Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of convertible senior notes due ...
CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private ...
InvestorsHub on MSN
CRISPR Therapeutics shares drop after announcing convertible notes sale
CRISPR Therapeutics AG (NASDAQ:CRSP) shares declined 6.75% on Tuesday after the company revealed plans to raise $350 million through a convertible senior notes offering. The gene-editing firm said it ...
In recent days, Dave Inc. completed a US$175,000,000 Rule 144A private offering of senior unsecured zero-coupon convertible notes due April 1, 2031, following the release of its fourth-quarter and ...
Hosted on MSN
Compass intends to offer $750M convertible senior notes in private offering, shares down
Compass (COMP) on Wednesday announced an intent to offer $750M of convertible senior notes due 2031 in a private offering. Shares were -3.14% pre-market to $10.49. The company said it intends to grant ...
Crescent Energy recently completed a private Rule 144A offering of US$600 million in 2.75% Convertible Senior Notes due March 15, 2031, with plans to redeem its higher-coupon 9.250% Senior Notes due ...
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced the pricing of its upsized offering of $350.0 million aggregate principal amount ...
SAINT HELIER, JE / ACCESS Newswire / January 20, 2026 / Caledonia Mining Corporation Plc (“Caledonia”) today announces the closing of its previously announced upsized offering of 5.875% Convertible ...
SAINT HELIER, JE / ACCESS Newswire / January 14, 2026 / Caledonia Mining Corporation Plc (“Caledonia”), a gold production, exploration and development company, today announced its intention to offer ...
CRISPR THERAPEUTICS ® standard character mark and design logo and SyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY ® and the CASGEVY logo are registered trademarks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results